Gastroesophageal Reflux Disease (GERD)
70
6
8
44
Key Insights
Highlights
Success Rate
85% trial completion
Published Results
15 trials with published results (21%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
11.4%
8 terminated out of 70 trials
84.6%
-1.9% vs benchmark
34%
24 trials in Phase 3/4
34%
15 of 44 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 44 completed trials
Clinical Trials (70)
Esophageal Cancer Risk Registry
Performance and Safety of Afluxin® in Patients With Gastroesophageal Reflux Disease
Evaluation of the Effectiveness of the Ezisurg Stapling (Ezi Endo Lite) During Laparoscopic Nissen Sleeve Gastrectomy
A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old
Effect of Breathing Training on Symptoms of Gastroesophageal Reflux Disease
Evaluation of the Clinical Course of NERD and Assessment of the Esophageal Mucosa Resistance
Endoscopic Cardial Constriction Ligation (ECCL) for Refractory GERD Using a Disposable Endoscope
Development of Machine Learning Models to Predict Postoperative GERD Symptom Resolution After Laparoscopic Nissen Fundoplication
Retrospective Observational Study on GERD Management in General Hospitals in Korea
A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-120 and AD-120A
Post-Market Registry for the Evaluation of RefluxStop in GERD Treatment
EFFICACY OF INSPIRATORY MUSCLE TRAINING ASSOCIATED WITH MANUAL TECHNIQUES IN INDIVIDUALS WITH GERD
Clinical Study Evaluating The Role of Vonoprazan Versus Pantoprazole in Patients With Gastroesophageal Reflux Disease
Indiana University Gastrointestinal Motility Diagnosis Registry
FODMAPs and Refractory GERD
Transoral Incisionless Fundoplication (TIF) for Laryngopharyngeal Reflux (LPR) Patients
Combined Scalp and Ear Acupuncture in Patients With Proton Pump Inhibitor- Dependent Gastroesophageal Reflux Disease
A Post-Approval Study of the LINX® Reflux Management System
Study to Evaluate the Performance and Safety of the MARIAL® in Association With PPI Versus PPI Alone
Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)